Ahrens Investment Partners’s Ocular Therapeutix OCUL Stock Holding History

Ahrens Investment Partners’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$42.2K	Buy	+8,000	New	+$38K	0.02%	355
2022 Q3	–	Sell	-8,000	Closed	-$32K	–	667
2022 Q2	$32K	Buy	8,000 +500	+7%	+$1.89K	0.01%	412
2022 Q1	$37K	Hold	7,500	–	–	0.01%	458
2021 Q4	$52K	Buy	+7,500	New	+$58.2K	0.02%	398
2020 Q1	–	Sell	-10,500	Closed	-$41K	–	158
2019 Q4	$41K	Buy	+10,500	New	+$36.5K	0.02%	166

Other funds holding OCUL

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ahrens Investment Partners's OCUL Position: Q1 2023 in Review

Ahrens Investment Partners opened a new position in Ocular Therapeutix (OCUL) in Q1 2023: 8,000 shares worth $42.2K. The stake represents 0.02% of the portfolio and ranks #355 among its holdings. This is a return to the name: Ahrens Investment Partners previously reported a position in OCUL as recently as Q2 2022.

Ahrens Investment Partners first reported a position in OCUL in Q4 2019 and has held it in 5 quarters since. The position peaked at $52K in Q4 2021. 127 funds tracked by Wall St. Rank hold OCUL as of Q1 2023.

Ahrens Investment Partners held 8,000 shares of Ocular Therapeutix worth $42.2K as of Q1 2023.
Ocular Therapeutix was a new Ahrens Investment Partners position in Q1 2023.
Ocular Therapeutix made up 0.02% of Ahrens Investment Partners's portfolio in Q1 2023, its #355 holding.
Ahrens Investment Partners first reported a position in Ocular Therapeutix in Q4 2019 and has held it in 5 quarters since.
Ahrens Investment Partners's Ocular Therapeutix position peaked at $52K in Q4 2021.
127 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2023.

Based on Ahrens Investment Partners's 13F filing for Q1 2023, filed 24 Apr 2023.